Canaccord Genuity analyst John Newman maintained a Buy rating on Aptose Biosciences (APTO) yesterday and set a price target of $13.00. The company’s shares closed last Monday at $7.34.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 13.5% and a 43.8% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Hutchison China MediTech, and Atara Biotherapeutics.
Aptose Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $11.33, which is a 36.5% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
Based on Aptose Biosciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $7.71 million. In comparison, last year the company had a GAAP net loss of $6.26 million.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of APTO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.
